July 7, 2025 10:46 AM EDT

Denali's Hunter syndrome therapy gets priority review; LENZ inks Canada deal

ENDPOINTS

Denali gets priority review for rare disease therapy: The program, called tividenofusp alfa, is designed to treat Hunter syndrome, a protein misfolding disease that begins …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

TRENDING NOW

Denali's Hunter syndrome therapy gets priority review; LENZ inks Canada deal

ENDPOINTS

Sign up to read this article for free.

Trump's tax cut law expands orphan drug exclusions, could upend 340B program

Clinician groups sue RFK Jr. and HHS over Covid-19 vaccine recommendation changes

FDA chief calls for 'meaningful' reduction of animal testing for new drugs

Apogee reports Phase 2 win for eczema drug that could challenge Dupixent and Ebglyss

Despite delay, KalVista wins FDA approval after Makary's short-lived attempt to intervene

Uncovering the Potential of Targeting the CD38 Pathway for Immune-Mediated Diseases

De­nal­i's Hunter syn­drome ther­a­py gets pri­or­i­ty re­view; LENZ inks Cana­da deal

ENDPOINTS

Sign up to read this article for free.

Trump's tax cut law ex­pands or­phan drug ex­clu­sions, could up­end 340B pro­gram

Clin­i­cian groups sue RFK Jr. and HHS over Covid-19 vac­cine rec­om­men­da­tion changes

FDA chief calls for 'mean­ing­ful' re­duc­tion of an­i­mal test­ing for new drugs

Apogee re­ports Phase 2 win for eczema drug that could chal­lenge Dupix­ent and Ebglyss

De­spite de­lay, KalVista wins FDA ap­proval af­ter Makary's short-lived at­tempt to in­ter­vene

Un­cov­er­ing the Po­ten­tial of Tar­get­ing the CD38 Path­way for Im­mune-Me­di­at­ed Dis­eases

Denali's Hunter syndrome therapy gets priority review; LENZ inks Canada deal

Trump's tax cut law expands orphan drug exclusions, could upend 340B program

Clinician groups sue RFK Jr. and HHS over Covid-19 vaccine recommendation changes

FDA chief calls for 'meaningful' reduction of animal testing for new drugs

Apogee reports Phase 2 win for eczema drug that could challenge Dupixent and Ebglyss

Despite delay, KalVista wins FDA approval after Makary's short-lived attempt to intervene

Uncovering the Potential of Targeting the CD38 Pathway for Immune-Mediated Diseases